Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Dec 15;15(4):611-614.
doi: 10.1093/ckj/sfab247. eCollection 2022 Apr.

Calciphylaxis after kidney transplantation: a rare but life-threatening disorder

Affiliations
Editorial

Calciphylaxis after kidney transplantation: a rare but life-threatening disorder

Manuel Alfredo Podestà et al. Clin Kidney J. .

Abstract

Calciphylaxis is a rare disorder characterized by vascular calcification and thrombosis of the subcutaneous microcirculation, leading to painful necrotic skin lesions and bearing a dreadfully high mortality rate. This syndrome is frequently also termed uraemic calcific arteriolopathy, since most cases are observed in patients with kidney failure. However, it is increasingly clear that calciphylaxis may also affect patients with normal or only slightly impaired renal function, including kidney transplant recipients. A precise definition of the characteristics and risk factors of calciphylaxis developing after kidney transplantation has been hindered by the extreme rarity of this condition, which also hampered the development of effective therapeutic strategies. In the present issue of CKJ, Guillén and colleagues report the largest case series of calciphylaxis in kidney transplant recipients to date, outlining several features that are apparently specific to this population. In this editorial, we briefly present the epidemiology and pathogenesis of calciphylaxis in different patient populations and discuss recent findings for its therapeutic management.

Keywords: calcific uraemic arteriolopathy; chronic kidney disease; renal transplantation; vascular calcification.

PubMed Disclaimer

Comment in

References

    1. Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med 2018; 379: 399–400 - PubMed
    1. Nigwekar SU, Zhao S, Wenger J et al. A nationally representative study of calcific uremic arteriolopathy risk factors. J Am Soc Nephrol 2016; 27: 3421–3429 - PMC - PubMed
    1. Brandenburg VM, Kramann R, Rothe H et al. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant 2017; 32: 126–132 - PubMed
    1. Weenig RH, Sewell LD, Davis MDP et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007; 56: 569–579 - PubMed
    1. Musso CG, Enz PA, Kowalczuk A et al. Differential diagnosis of calciphylaxis in chronic dialysis patients. Int Urol Nephrol 2020; 52: 595–597 - PubMed

Publication types